Biologic effects of delta-8-estrone sulfate in postmenopausal women

Journal of the Society for Gynecologic Investigation

Volumn 5, Issue 3, 1998, Pages 156-160

  Bhavnani, Bhagu R ^a   Cecutti, Anthony ^a   Dey, Mike S ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b WYETH AYERST RESEARCH   (United States)

Author keywords

Delta 8 estrone sulfate; N telopeptide; Oxidation lag time; Oxidized low density lipoprotein

Indexed keywords

CONJUGATED ESTROGEN; DELTA8 ESTRONE SULFATE; ESTRONE SULFATE; HORMONE BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ADULT; AMENORRHEA; ARTICLE; CARDIOVASCULAR EFFECT; CHOLESTEROL BLOOD LEVEL; DRUG ACTIVITY; ESTROGEN ACTIVITY; FEMALE; HORMONAL THERAPY; HORMONE BINDING; HORMONE BLOOD LEVEL; HUMAN; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; URINE LEVEL;

CHOLESTEROL; CHOLESTEROL, HDL; COLLAGEN; COLLAGEN TYPE I; ESTROGENS, CONJUGATED (USP); ESTRONE; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LIPOPROTEINS, LDL; LUTEINIZING HORMONE; MIDDLE AGED; PEPTIDES; POSTMENOPAUSE; SEX HORMONE-BINDING GLOBULIN; TRANSCORTIN;

EID: 0031864631     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-5576(98)00003-3     Document Type: Article

References (28)

1. Bhavnani BR. The saga of the ring B unsaturated equine estrogens. Endocr Rev. 9:1988;396-416.
2. Bhavnani BR, Gerulath A, Cecutti A. Pharmacokinetics and pharmacodynamics of delta-8-estrone. J Soc Gynecol Invest. 3:(Suppl 2):1996;364A.
3. Allain CB, Poon LS, Chan FCS, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 20:1974;470-475.
4. Friedewald WT, Levy RI, Fredickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
5. Quintanilha AT, Packer L, Szyszlo Davies JM, Racanelli TL, Davies KJA. Membrane effects of vitamin E deficiency Bioenergetic and surface charge density studies of skeletal muscle and liver mitochondria . Ann N Y Acad Sci. 393:1986;32-47.
6. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res. 6:1989;67-75.
7. Hanson DA, Weis MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption Quantitation of type 1 collagen cross-linked n-telopeptide in urine . J Bone Miner Res. 7:1992;1251-1258.
8. Chesnut CH, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women Urinary n-telopeptide of type 1 collagen monitors therapeutic effect and predicts response of bone mineral density . Am J Med. 102:1997;29-37.
9. Howard RP, Keaty KC. Evaluation of equilin-3-monosulfate and other estrogens. Arch Int Med. 128:1971;229-234.
10. Beek VA, Friedrich F. Equilin sulfat zur substitution beim menopause-syndrom. Wien Klin Wochensch. 87:1975;59-62.
11. Lobo RL, Nguyen HN, Eggena P, Brenner PF. Biologic effects of equilin sulfate in postmenopausal women. Fertil Steril. 49:1988;234-338.
12. Artner J, Friedrich F. Die behandlung des klimaklerichen syndroms mit dihydroequilin. Wien Klin Wochensch. 82:1970;275-277.
13. Bhavnani BR. Pharmacokinetics and pharmacodynamics of conjugated equine estrogens Chemistry and metabolism . Proc Soc Exp Biol Med. 217:1998;6-16.
14. Bhavnani BR, Cecutti A. Metabolic clearance rate of equilin sulfate and its conversion to plasma equilin, conjugated and unconjugated equilenin, 17β-dihydroequilin, and 17β-dihydroequilenin in normal postmenopausal women and men under steady state conditions. J Clin Endocrinol Metab. 77:1993;1269-1274.
15. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med. 325:1991;756-762.
16. Bush TL, Barrett-Conner E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogens in women. Results from the Lipid Research Clinics Programs Follow-up Study. Circulation. 75:1987;1102-1109.
17. Sullivan JM, Fowlkes LP. The clinical aspects of estrogen and cardiovascular system. Obstet Gynecol. 87:(Suppl 2):1996;36S-43S.
18. Grodstein F, Stampfer M, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 335:1996;453-461.
19. Steinberg F, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol Modifications of low-density lipoprotein that increases its atherogenicity . N Engl J Med. 320:1989;915-924.
20. Huber LA, Scheffler E, Poll T, Ziegler R, Dressel HA. 17β-estradiol inhibits LDL oxidation and cholesterol ester formation in cultured macrophages. Free Radic Res. 8:1990;167-175.
21. Maziere C, Auclair M, Ronveaux MC, Salmon S, Santus R, Maziere JC. Estrogens inhibit copper and cell-mediated modifications of low density lipoprotein. Atherosclerosis. 89:1991;175-182.
22. Subbiah MTR, Kessel B, Agrawal M, et al. Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrinol Metab. 77:1993;1095-1097.
23. Sack MN, Rader DJ, Cannon RO. Oestrogen and inhibition of low density lipoproteins in postmenopausal women. Lancet. 343:1994;269-270.
24. Tang M, Abplenalp W, Ayres S, Subbiah MTR. Superior and distinct antioxidant effects of selected estrogen metabolites on lipid peroxidation. Metabolism. 45:1996;411-414.
25. Wilcox JG, Sevanian A, Hwang J, Stanczyk FZ, Hodis HN, Lobo RA. Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. Fertil Steril. 67:1997;57-62.
26. Bhavnani BR, Cecutti A, Gerulath A, Woolever CA. Are cardiovascular benefits associated with conjugated equine estrogen therapy and red wine consumption a result of the antioxidant properties of their components? J Soc Gynecol Invest. 4:(Suppl 1):1997;106A.
27. Wilcox JG, Hwang J, Gentzschein EK, et al. Effects of combined estrogen and progestin therapy in postmenopausal women on endothelin levels and oxidation of LDL. J Soc Gynecol Invest. 3:(Suppl 2):1996;69A.
28. Bhavnani BR, Cecutti A. Comparison of antioxidant effects of Premarin, Premarin plus progestin and generic conjugated estrogen (C.E.S.) administration in postmenopausal women. J Soc Gynecol Invest. 4:(Suppl 1):1997;176A.